HCPLive

Hearing Loss Linked to Cognitive Impairment in Elderly Patients

 
MONDAY, Jan. 21 (HealthDay News) -- For older adults, hearing loss is independently associated with incident cognitive impairment; and about 11 percent of those aged 80 or older have dual sensory impairment (DSI), according to two studies published online Jan. 21 in JAMA Internal Medicine.

Frank R. Lin, M.D., Ph.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues examined whether hearing loss is independently correlated with accelerated cognitive decline among 1,984 older adults without prevalent cognitive impairment at baseline. The researchers found that, compared to those with normal hearing, among the 1,162 individuals with baseline hearing loss, the annual rates of cognitive decline were 41 percent greater on the Modified Mini-Mental State Examination score and 32 percent greater on the Digit Symbol Substitution test scores. Compared to those with normal hearing, individuals with hearing loss at baseline had a significantly increased risk (24 percent greater) for incident cognitive impairment.

Bonnielin K. Swenor, M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined the prevalence of DSI in hearing and vision using data from the 1999 to 2006 cycles of the National Health and Nutritional Examination Survey. The researchers found that approximately 1.5 million Americans aged 20 years and older had DSI. The prevalence of DSI was less than 1 percent for individuals younger than 70 years and was 11.3 percent for those aged 80 or older. Only 19 percent of those aged 80 or older were free of any sensory impairment.

"Concurrent vision impairment could potentially accelerate the rate of cognitive decline and dementia previously reported in individuals with hearing impairment alone," Swenor and colleagues conclude.

An author associated with both studies disclosed financial ties to Pfizer and Cochlear Europe.
 

Abstract - Lin
Full Text (subscription or payment may be required)
 
Abstract - Swenor
Full Text (subscription or payment may be required)
 
Editorial (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
Stress is both a cause of and product of inequality, according to a study published in Psychoneuroendocrinology.
As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
$vAR$